Impaired inhibition by dexamethasone of cytokine release by alveolar macrophages from patients with chronic obstructive pulmonary disease.
about
Cigarette smoke induces IL-8, but inhibits eotaxin and RANTES release from airway smooth muscle.The Role of Innate and Adaptive Immune Cells in the Immunopathogenesis of Chronic Obstructive Pulmonary DiseaseAlpha,beta-unsaturated aldehydes in cigarette smoke release inflammatory mediators from human macrophagesLow dose theophylline showed an inhibitory effect on the production of IL-6 and IL-8 in primary lung fibroblast from patients with COPDGlucocorticoid insensitivity as a future target of therapy for chronic obstructive pulmonary diseaseSUV39H1 Reduction Is Implicated in Abnormal Inflammation in COPD.Lung chitinolytic activity and chitotriosidase are elevated in chronic obstructive pulmonary disease and contribute to lung inflammation.IL-17A Monoclonal Antibody Partly Reverses the Glucocorticoids Insensitivity in Mice Exposed to Ozonec.A unique protein profile of peripheral neutrophils from COPD patients does not reflect cytokine-induced protein profiles of neutrophils in vitroTargeting phosphoinositide-3-kinase-delta with theophylline reverses corticosteroid insensitivity in chronic obstructive pulmonary disease.Comparison of the anti-inflammatory effects of Cilomilast, Budesonide and a p38 Mitogen activated protein kinase inhibitor in COPD lung tissue macrophages.Inhibition by red wine extract, resveratrol, of cytokine release by alveolar macrophages in COPDAnti-inflammatory effects of resveratrol in lung epithelial cells: molecular mechanisms.Nontypeable Haemophilus influenzae in chronic obstructive pulmonary disease and lung cancer.Evaluation of glucocorticoid receptor function in COPD lung macrophages using beclomethasone-17-monopropionate.Smoking status and anti-inflammatory macrophages in bronchoalveolar lavage and induced sputum in COPD.Reversal of corticosteroid insensitivity by p38 MAPK inhibition in peripheral blood mononuclear cells from COPD.Lung inflammation changes and oxidative stress induced by cigarette smoke exposure in guinea pigs affected by Zataria multiflora and its constituent, carvacrol.How corticosteroids control inflammation: Quintiles Prize Lecture 2005Chronic obstructive pulmonary disease, pollution, pulmonary vascular disease, transplantation, pleural disease, and lung cancer in AJRCCM 2003.Use of low-dose oral theophylline as an adjunct to inhaled corticosteroids in preventing exacerbations of chronic obstructive pulmonary disease: study protocol for a randomised controlled trial.Serum amyloid A opposes lipoxin A₄ to mediate glucocorticoid refractory lung inflammation in chronic obstructive pulmonary diseaseOutcomes in COPD patients receiving tiotropium or salmeterol plus treatment with inhaled corticosteroidsThe effects of corticosteroids on COPD lung macrophages: a pooled analysisInhibitory effect of p38 mitogen-activated protein kinase inhibitors on cytokine release from human macrophagesDifferential Effects of p38, MAPK, PI3K or Rho Kinase Inhibitors on Bacterial Phagocytosis and Efferocytosis by Macrophages in COPD.Histone deacetylase 2-mediated deacetylation of the glucocorticoid receptor enables NF-kappaB suppressionTargeting histone deacetylase 2 in chronic obstructive pulmonary disease treatment.Theophylline restores histone deacetylase activity and steroid responses in COPD macrophages.Regulation of YKL-40 expression by corticosteroids: effect on pro-inflammatory macrophages in vitro and its modulation in COPD in vivo.Pulmonary biomarkers in chronic obstructive pulmonary disease.Combination therapy for airflow limitation in COPD.Emerging drugs for the treatment of chronic obstructive pulmonary disease.Alveolar macrophages as orchestrators of COPD.Aspects on pathophysiological mechanisms in COPD.The cytokine network in asthma and chronic obstructive pulmonary diseaseTargeting systemic inflammation: novel therapies for the treatment of chronic obstructive pulmonary disease.Antioxidant therapies in COPD.Deacetylases and NF-kappaB in redox regulation of cigarette smoke-induced lung inflammation: epigenetics in pathogenesis of COPD.Future therapeutic treatment of COPD: struggle between oxidants and cytokines
P2860
Q24814252-AFD9337A-4FC9-482F-9407-60A3A7A3E1B8Q26771902-10A8EE4C-E814-423A-88FB-F77F5659CDC2Q28307870-3F807768-E0CB-4EFB-9269-880DC5ABB355Q28396352-96BF879E-2390-4913-B5D2-A876D7D481F9Q28761895-7F5B2764-6517-4938-A7A9-91AE35A5A6B3Q33582967-9ECC5B43-977D-47CA-8E00-96F061BAEEEBQ33597102-3F68E3F2-9DFF-4611-A71A-3BD871B03B45Q33676504-BDA3C413-6ED1-459D-816C-EF3DBFC1519FQ34012362-94AFA1CC-79EE-4C3A-9C38-3632689BF220Q34103575-241F5081-786E-4CCD-BC80-CFBC9B20F156Q34475700-0DC9B1FB-8303-4C27-AC90-DBBADF9870ACQ34542927-91F2394C-9717-4C44-BC59-3BAB2688FDC9Q34548393-802DA646-A109-4E0E-944B-495013DE3334Q34621087-D9A6EF90-BB0F-4B6D-944B-AA6C286305D8Q34738020-0010EF5A-2776-41BA-9C1F-53AB83D4BD40Q34774344-277D6DF8-FC73-4E41-AF26-6F4B38F7B9A8Q35067454-DD5F4F53-B023-4E2B-84A8-DBD4A4EDB12CQ35163360-9C6C6F57-22A8-46F0-A1FC-CDDB5551E6E0Q35545886-F8EEFFFC-30CF-480A-B2DE-A5F8F0901A76Q35626624-9A86E395-B4C5-4199-AB2A-DDD0D82F81D6Q35733010-1231FC2C-7DB2-4804-89C7-76509E3AB460Q35734988-8D825885-63E2-4D3D-B514-6AF8839C5151Q35876509-69A4CB56-1D79-4DBB-BFFE-7C18C75FC2FFQ35985973-0FA38932-4AE3-4296-869E-A0ECC4A9FD13Q35995739-FBBAF9CE-6C70-4712-8C67-9326458DA85AQ36146801-9208F965-8BDF-48F1-A26C-44772968EB8FQ36227904-1FA616D8-F950-4A24-8996-1938B0EC6495Q36318525-19F73F1A-8CBE-4FA3-961F-155916A8F142Q36402442-E52297E0-2789-4BEB-88A1-B62644D70C5DQ36424863-948B0E4A-F407-4A21-8479-194FBAC22865Q36429908-DE018FEE-AC9C-4E68-A87D-748B335E04A9Q36445725-30BF8906-6419-42FC-A7D9-AC7A948E1FA1Q36458412-2309064D-ACAB-4C3C-B693-9C7372DA4C32Q36602291-5961A561-1379-4C96-9D04-D5DE01B8C299Q36909567-518ED056-A057-4FC3-AF1A-982293EB3E66Q36955575-E745F0E4-721D-40ED-8587-A5EA452EFA47Q36956720-3F085785-084F-4ECE-8DA4-A5A8D437AEA5Q37018914-AC9CB443-2F39-4454-B547-D18DB06B12E8Q37065224-71F9A2F9-5A78-4827-BD0F-E5B6AC794B82Q37071004-F0E45022-BC0C-4426-9313-4515C287FAEF
P2860
Impaired inhibition by dexamethasone of cytokine release by alveolar macrophages from patients with chronic obstructive pulmonary disease.
description
2002 nî lūn-bûn
@nan
2002年の論文
@ja
2002年学术文章
@wuu
2002年学术文章
@zh-cn
2002年学术文章
@zh-hans
2002年学术文章
@zh-my
2002年学术文章
@zh-sg
2002年學術文章
@yue
2002年學術文章
@zh
2002年學術文章
@zh-hant
name
Impaired inhibition by dexamet ...... obstructive pulmonary disease.
@en
Impaired inhibition by dexamet ...... obstructive pulmonary disease.
@nl
type
label
Impaired inhibition by dexamet ...... obstructive pulmonary disease.
@en
Impaired inhibition by dexamet ...... obstructive pulmonary disease.
@nl
prefLabel
Impaired inhibition by dexamet ...... obstructive pulmonary disease.
@en
Impaired inhibition by dexamet ...... obstructive pulmonary disease.
@nl
P2093
P2860
P921
P1476
Impaired inhibition by dexamet ...... obstructive pulmonary disease.
@en
P2093
Carmen De Matos
Duncan F Rogers
Louise E Donnelly
Peter J Barnes
Richard E K Russell
Sarah V Culpitt
P2860
P356
10.1164/RCCM.200204-298OC
P407
P577
2002-09-17T00:00:00Z